Advanced search    

Search: authors:"Douglas L. Arnold"

8 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study

Biogen (Cambridge, MA, USA). Douglas L. Arnold has received honoraria from Acorda Therapeutics, Bayer HealthCare, Biogen, Coronado Biosciences, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, MedImmune

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Histamine H3 receptor blockade may enhance lesion remyelination in multiple sclerosis (MS). The efficacy (using a magnetic resonance imaging marker of myelination, magnetisation transfer ratio [MTR]), safety and pharmacokinetics of GSK239512, a potent and brain penetrant H3 receptor antagonist/inverse agonist on lesion remyelination in relapsing-remitting MS (RRMS) were assessed...

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

employee of Biogen. Douglas L. Arnold reports an equity interest in NeuroRx during the conduct of the study and personal fees from Biogen, EMD Serono, Genentech, Genzyme, Hoffman-La Roche, Innate

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

manuscript for submission. Financial support for this study was provided by Teva Pharmaceutical Industries, Ltd., Israel. Conflicts of interest Douglas L. Arnold, MD, has provided advisory, consultancy, and

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

sclerosis Douglas L Arnold 0 1 Peter A Calabresi Bernd C Kieseier Sarah I Sheikh Aaron Deykin Ying Zhu Shifang Liu Xiaojun You Bjoern Sperling Serena Hung 0 NeuroRx Research , Montreal, QC , Canada 1

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

We measured changes in brain magnetization transfer ratio (MTR) as a potential indicator of myelin density in brain tissue of patients with relapsing-remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) in the Phase 3 DEFINE study. DEFINE was a randomized, double-blind, placebo-controlled study in which patients with RRMS were randomized 1:1:1...

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

In the Phase 3 DEFINE study, delayed-release dimethyl fumarate (DMF) 240 mg twice (BID) and three times daily (TID) significantly reduced the mean number of new or enlarging T2-hyperintense lesions and gadolinium-enhancing (Gd+) lesion activity at 2 years in patients (MRI cohort; n = 540) with relapsing–remitting MS. The analyses described here expand on these results by...

Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis

Introduction Onset of MS occurs during childhood in about 5% of cases. It is unclear whether very young age at MS onset, when the nervous system is still myelinating, affects MS lesion accrual or regional distribution. Objective To compare the frequency, volume and distribution of T2 and T1 lesions in children and adults with relapsing-remitting multiple sclerosis (RRMS). Methods...